NCT00847015 - Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Bladder CancerUrinary Bladder

Interventions

DRUG

Sunitinib

Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.

DRUG

Gemcitabine

Gemcitabine 1,000 mg/m\^2

DRUG

cisplatin

cisplatin 35 mg/m\^2 will be administered intravenously on days 1 and 8.

Trial Locations (5)

Memorial Sloan-Kettering Cancer Center, New York

Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre

Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack

Memorial Sloan-Kettering at Basking Ridge, Basking Ridge

Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow